Evidence map›Paper›PMID 37130343›Full record

ArticleJournal of medicinal chemistry2023

Thomas Lane, Vadim Makarov, Julie A E Nelson, Rick B Meeker, Giuseppina Sanna, Olga Riabova, Elena Kazakova, Natalia Monakhova, Andrey Tsedilin, Fabio Urbina and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. 1-Sulfonyl-3-amino-1ACS omega · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Thomas LaneCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.ORCID 0000-0001-9240-4763
Vadim MakarovResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, 119071, Moscow 119071, Russia.
Julie A E NelsonDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Rick B MeekerDepartment of Neurology, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Giuseppina SannaDepartment of Biomedical Science, University of Cagliari, Monserrato 09042, Italy.
Olga RiabovaResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, 119071, Moscow 119071, Russia.
Elena KazakovaResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, 119071, Moscow 119071, Russia.
Natalia MonakhovaResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, 119071, Moscow 119071, Russia.
Andrey TsedilinResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, 119071, Moscow 119071, Russia.
Fabio UrbinaCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.
Thane JonesCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.
Ashley SuchyDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Sean EkinsCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.ORCID 0000-0002-5691-5790
Collaborations Pharmaceuticals (United States) · USUniversity of North Carolina at Chapel Hill · USUniversity of Cagliari · IT

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Centralized assay datasets for modelling support of small drug discovery organizationsR44GM122196 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2018 to 2022
$3.3M
New generation of non-nucleoside RT HIV inhibitors avoiding HIV-associated neurocognitive disordersR01NS102164 · NINDS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN, NELSON, JULIE AE · 2017 to 2019
$587k
MegaTox for analyzing and visualizing data across different screening systemsR43ES031038 · NIEHS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2019 to 2020
$349k
NIAID NIH HHS P30 AI050410NIEHS NIH HHS R43 ES031038NIGMS NIH HHS R44 GM122196NINDS NIH HHS R01 NS102164
6 · The paper itself

Abstract

Highly active antiretroviral therapy (HAART) has revolutionized human immunodeficiency virus (HIV) healthcare, turning it from a terminal to a potentially chronic disease, although some patients can develop severe comorbidities. These include neurological complications, such as HIV-associated neurocognitive disorders (HAND), which result in cognitive and/or motor function symptoms. We now describe the discovery, synthesis, and evaluation of a new class of

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsAnimalsAntiretroviral Therapy, Highly ActiveHIV Reverse TranscriptaseHumansMiceReverse Transcriptase InhibitorsAnti-HIV AgentsHIV Reverse TranscriptaseReverse Transcriptase Inhibitors

Identifiers

PMID37130343
PMCPMC10269403
OpenAlexW4367670311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.